In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Iressa (AstraZeneca)
- INDICATIONS: Advanced non-small cell lung cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Tyrosine kinase inhibitor
- HALF-LIFE: 48 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antifungals, BCG Vaccine, Boceprevir, Carbamazepine, Cardiac glycosides, Clozapine, Conivaptan, CYP3A4 inhibitors and inducers, Dasatinib, Deferasirox, Denosumab, Echinacea, Efavirenz, Grapefruit Juice, Itraconazole, Leflunomide, Natalizumab, Phenobarbital, Phenytoin, Pimecrolimus, Ranitidine, Rifampin, Rifapentine, Sipuleucel-T, St John's Wort, Tacrolimus, Topotecan, Trastuzumab, Vaccines, Vitamin K antagonists, Voriconazole, Warfarin
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Epidermal growth factor receptor (EGFR) inhibitor / antagonist
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of gefitinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/12/2025
